{"url_path":"/sec/rgpx/8-k/2026-06-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1357878/0001472375-26-000167-index.html","accession_number":"0001472375-26-000167","cik":"0001357878","ticker":"RGPX","issuer_name":"REGENEREX PHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1357878/0001472375-26-000167-index.html","primary_entity_key":"0001357878","primary_entity_name":"REGENEREX PHARMA, INC."},"word_count":298,"has_tables":true,"body_markdown":"Filed by Avantafile.com - Regenerex Pharma, Inc. - Form 8-K\n\n0001357878\nfalse\n\n0001357878\n\n2026-06-11\n2026-06-11\n\niso4217:USD\nxbrli:shares\n\niso4217:USD\nxbrli:shares\n\nxbrli:pure\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, DC 20549**\n\n** **\n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the\nSecurities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event\nreported): June 11, 2026\n\n \n\n**REGENEREX PHARMA, INC**\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n**Nevada**\n\n \n\n**000-53230******\n\n \n\n**98-0479983******\n\n(State or Other Jurisdiction\n\nof Incorporation)\n\n \n\n(Commission File Number)\n\n \n\n(IRS Employer Identification No.)\n\n \n\n**5348 Vegas Drive #177**\n\n**Las Vegas, NV**\n\n \n\n**89108**\n\n(Address of Principal Executive Offices)\n\n \n\n(Zip Code)\n\n \n\nRegistrant’s telephone number, including area\ncode: **(877) 761-7479**\n\n  \n\nCheck the appropriate box below if the Form 8-K filing\nis intended to simultaneously satisfy the filing obligation of the registrant\nunder any of the following provisions (*see* General Instruction A.2.\nbelow):\n\n \n\n \n\n[ ]\n\nWritten communications pursuant to Rule 425 under\nthe Securities Act (17 CFR 230.425)\n\n \n\n \n\n[ ]\n\nSoliciting material pursuant to Rule 14a-12 under\nthe Exchange Act (17 CFR 240.14a-12)\n\n \n\n \n\n[ ]\n\nPre-commencement communications pursuant to Rule\n14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n \n\n[ ]\n\nPre-commencement communications pursuant to Rule\n13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))\n\n \n\nSecurities registered pursuant to Section\n12(b) of the Act: None.\n\n \n\nIndicate by check mark whether the registrant is an\nemerging growth company as defined in Rule 405 of the Securities Act of 1933\n(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of\n1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company [X]\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has\nelected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section\n13(a) of the Exchange Act. [ ]"}